Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Anlotinib + Chemotherapy in First-line ES-SCLC
NCT04660097Phase 2Completed
- Sponsor
- Henan Cancer Hospital
- Start
- May 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in small cell lung cancer (SCLC), sponsored by Henan Cancer Hospital. Started May 2021; status: completed.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04660097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660097.